Navigation Links
Drug Duo May Help Fight Aggressive Form of Breast Cancer
Date:1/17/2012

By Kathleen Doheny
HealthDay Reporter

TUESDAY, Jan. 17 (HealthDay News) -- Combining two drugs that target an aggressive type of breast cancer known as HER2-positive appears to work better than using either drug alone, researchers report.

The dual-drug approach greatly boosted the chances of eliminating microscopic signs of early cancer by the time a woman was due to have surgery, said researcher Dr. Jose Baselga, chief of hematology/oncology at Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School.

The study was published online Jan. 17 in The Lancet.

The two drugs are Tykerb (lapatinib) and Herceptin (trastuzumab). Using both together resulted in a 51 percent response, compared with a 30 percent response in women given Herceptin alone. Those given Tykerb alone had a 25 percent response.

"What we observed was a massive improvement in response," Baselga said.

GlaxoSmithKline, the maker of Tykerb, helped fund the study.

"Lapatinib was approved for advanced breast cancer in 2007," Baselga said. "The question we had was, what is the efficacy if we give it in early-stage breast cancer prior to surgery?"

Baselga and his colleagues conducted a trial treating 455 women from 23 countries. All had HER2-positive breast cancers. All had tumors larger than about three-fourths of an inch.

In HER2-positive breast cancer, test results are positive for a protein called human epidermal growth factor receptor 2, which promotes cancer cell growth.

In the study, 154 women got Tykerb, 149 Herceptin and the other 152 both drugs. All had the drug regimen before surgery, with Taxol (paclitaxel), a standard chemotherapy, added after six weeks. After 12 more weeks of treatment, the women had surgery.

At that point, researchers evaluated who had better responses. The women continued the treatments for one more year, allowing researchers to follow them and see how the approaches affected survival.

Baselga stressed that the study looked only at women with early-stage HER2-positive breast cancers, and that the drug Tykerb is approved now only for advanced breast cancers.

The study is well done and important, said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society. The two drugs, he said, "affect the same pathway but do it in a different way."

While the combination showed a better response rate, "there is also an increased level of side effects," he noted.

While no major heart problems occurred, those on Tykerb alone or the two-drug combination had more diarrhea. Liver-enzyme alterations were also more frequent when Tykerb was used.

GlaxoSmithKline notes that liver toxicity with the drug may be severe and that deaths have been reported, although the cause of the deaths has not been determined.

The important question, however, has not been answered yet, Lichtenfeld said. That's the effect on overall survival in using the two-drug approach. The researchers are continuing to evaluate that.

In another study, published online Jan. 17 in The Lancet Oncology, researchers from Germany reported that Tykerb is less beneficial than Herceptin as a single-drug therapy.

They assigned 620 women with HER2-positive breast cancer to get standard chemotherapy plus Herceptin or Tykerb.

They looked to see which drug was better at eliminating invasive cancer in the breast and metastatic cells in the lymph nodes. While 30 percent of those in the Herceptin group had this response, 23 percent of the Tykerb group did. The study was funded by drug makers GlaxoSmithKline, Roche and Sanofi-Aventis.

Baselga reports receiving honoraria from Roche; other co-authors report receiving speaking fees or honoraria from GlaxoSmithKline and fees from other drug companies.

More information

To learn more about breast cancer, including HER2-positive cancers, visit the American Cancer Society.

SOURCES: Jose Basegla, M.D., Ph.D., chief, hematology/oncology, Massachusetts General Hospital Cancer Center, and professor, medicine, Harvard Medical School, Boston; Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society; Jan. 17, 2012, The Lancet, The Lancet Oncology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. MARA Fights Malaria With WaveMaker and Amazon Web Services
2. NASBE Supports First Lady Michelle Obama in Fight Against Childhood Obesity
3. Planting Seeds to Fight Childhood Obesity
4. AMA Joins First Lady in Fight Against Childhood Obesity
5. A common cholesterol drug fights cataracts, too
6. In Support of the Lets Move Campaign to Fight Childhood Obesity, Verizon Thinkfinity Providing Free Educational Resources on Nutrition and Exercise
7. The Alliance for a Healthier Generation Names Celtics Captain Paul Pierce National Athlete Spokesperson in the Fight Against Childhood Obesity
8. Tiny fruit fly could offer big clues in fight against obesity, researcher says
9. Family's Fight to Save Child Spreads Hope Around Globe
10. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
11. 29 Clear Channel stations Nationwide Raise Nearly $2.8 Million to Help Save the Lives of Kids Fighting Cancer and Other Deadly Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Duo May Help Fight Aggressive Form of Breast Cancer 
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... Canadian Celiac Association (CCA), is pleased to announce the launch of the ... nutritional articles, recipes, and more. The purpose of the GFCP Scoop ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... 27, 2016   ... in Recurring Consumable Sales  Clinical sales grow ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... for the first quarter ended March 31, 2016 and ... of its commercial strategy. First Quarter 2016 ...
Breaking Medicine Technology: